Clinical trials: Cancer, Head
Nasopharyngeal Carcinoma
The Value of Post-radiation Detectable Plasma EBV DNA in High-risk Nasopharyngeal Carcinoma Patients
An additional blood test at 2-3 months after RT is a valuable biomarker in predicting treatment outcome for NPC patients. Patients with persistently detectable EBV DNA during re-staging survey 2-3 months after RT should…
- Trial name
- NCT03981224
- Volunteers
- 706 people, healthy volunteers welcome
- Sponsor
- Taichung Veterans General Hospital
HEAD & NECK Cancer
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
The purpose of this study is to test the safety of RAD001 (everolimus) tablets at different dose levels, when added to docetaxel and cisplatin.
- Trial name
- NCT00935961
- Testing
- RAD001 + docetaxel + cisplatin
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer
Hyperimmune Colostrum and Oral Mucositis
To study the effect of daily intake of hyperimmune colostrum on prevention and treatment of oral mucositis in patients with head and neck cancer undergoing high-dose radiation.
- Trial name
- Mucositis (NCT00699569)
- Testing
- hyperimmune colostrum
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Locally Advanced Head and Neck Carcinoma
Pea Protein Oral Nutrition Supplement for the Reduction of Gastrostomy Tube Placement Rate in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiation Therapy
This phase II trial studies the effect of a plant-based oral nutrition supplement, Kate Farms Standard 1.4 and/or Standard 1.0. as a primary source of nutrition in reducing the gastrostomy tube placement rate in patients with…
- Trial name
- NCT05115760
- Testing
- Dietary Supplement, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Head and Neck Squamous Cell Carcinoma
Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC
The purpose of this trial is to determine the efficacy of the immunotherapy with MVX-ONCO-1 in patients with advanced head and neck squamous cell carcinoma.
- Trial name
- NCT02999646
- Testing
- MVX-ONCO-1
- Where
- 4 sites in Switzerland
- Volunteers
- 16 people
- Sponsor
- Maxivax SA
Histopathological Diagnosis of Nasopharyngeal Carcinoma, Patients with Nasopharyngeal Carcinoma Without Distant Metastases After AJCC/UACC 8th Edition
Prognostic Value of CD4/CD8 Ratio in Patients with Nasopharyngeal Carcinoma
In our previous retrospective study, we identified circulating immune cell counts and the CD4/CD8 ratio as significant prognostic markers in nasopharyngeal carcinoma.
- Trial name
- NCT06762470
- Where
- China
- Volunteers
- 325 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Thyroid Neoplasms
Clinical Efficacy of 125I Seed Implantation in the Treatment of Refractory Differentiated Thyroid Cancer
A retrospective analysis was conducted on RAIR-DTC patients who underwent radioactive 125I seed implantation from January 2015 to February 2022 at Jiangxi Cancer Hospital. Prescription dose: 80~120 Gy.
- Trial name
- NCT06362772
- Testing
- Iodine-125 brachytherapy
- Volunteers
- 36 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Acupuncture
Efficacy of Acupuncture in Radiotherapy-induced Dysphagia in Patients With Head and Neck Cancer
Purpose: Rationale: Acupuncture is a therapy for physical activity disorders secondary to nervous diseases, and it may have therapeutic effects on dysphagia caused by radiation therapy.
- Trial name
- NCT03336775
- Testing
- acupuncture
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nasopharyngeal Carcinoma, Radiation-induced Xerostomia
Impact on Xerostomia for Nasopharyngeal Carcinoma Patients Treated With or Without Superficial Parotid Lobe-sparing Intensity-modulated Radiotherapy
This is a prospective phase II clinical randomized controlled study, the purpose of this study is to assess whether superficial parotid lobe-sparing intensity-modulated radiotherapy (SPLS-IMRT) can decrease the incidence of…
- Trial name
- NCT05020067
- Testing
- superficial parotid lobe-sparing intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sun Yat-sen University
Squamous Cell Carcinoma of the Head and Neck
Hyperbaric Radiation Sensitization of Head and Neck Cancers
There is reason to believe that hyperbaric oxygen administered immediately prior to radiotherapy will prove beneficial for this cancer type and stage.
- Trial name
- NCT03843671
- Testing
- Hyperbaric oxygen, Hyperbaric chamber
- Where
- 5 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- National Baromedical Services
Head and Neck Neoplasms, Carcinoma, Squamous Cell of Head and Neck
Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma
This is a Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of VCN-01 in Combination With Durvalumab (MEDI4736) in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
- Conditions
- Head and Neck Neoplasms, Carcinoma, Squamous Cell of Head and Neck, Metastasis, Recurrence
- Trial name
- NCT03799744
- Testing
- VCN-01, Durvalumab
- Where
- 2 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Institut Català d'Oncologia
Head and Neck Squamous Cell Carcinoma
Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
In phase I of the trial, the investigators aim to explore the safety and feasibility of abemaciclib in combination with nivolumab in patients with recurrent/metatstatic head and neck squamous cell carcinoma (RM-HNSCC).
- Trial name
- NCT03655444
- Testing
- Abemaciclib, Nivolumab, Tumor biopsy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Washington University School of Medicine
Children, Only, Traumatic Brain Injury
Neurophysiological Measurements Using the NeuroCatch™ Platform in Pediatric Concussion
EEG signals have been collected and studied since the early 1990's as a way of assessing brain function at a gross level. As early as the 1930's a derivative of the raw EEG signal - event-related potentials (ERPs) - have been…
- Conditions
- Children, Only, Traumatic Brain Injury, Concussion, Mild, Pediatric ALL
- Trial name
- NCT03889483
- Testing
- NeuroCatch™ Platform
- Where
- Canada
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Dr. Michael Esser
Head and Neck Cancer
Treatment Selection According to Skin Reaction to Cetuximab
The therapy of patients with locally advanced head and neck cancer will be adjusted to the grade of skin rush as recorded after the first two cycles of Cetuximab and Cisplatin, i.e.
- Trial name
- NCT01472653
- Testing
- cisplatin, radiotherapy, cetuximab
- Where
- Slovenia
- Volunteers
- 120 people
- Sponsor
- Institute of Oncology Ljubljana
Patient Reported Outcome Measures, Colorectal Cancer
Predicting Disease Progression and/or Recurrence in Cancer
This is a prospective study addressing the challenge of predicting disease progression and/or recurrence in patients diagnosed with metastatic colorectal, pancreatobiliary, or esophagogastric cancer that are receiving anti-cancer…
- Conditions
- Patient Reported Outcome Measures, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer
- Trial name
- NCT04776837
- Testing
- Observational Cohort
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer, Colorectal Cancer
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.
- Conditions
- Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma
- Trial name
- STARLING (NCT05576077)
- Testing
- TBio-4101, Pembrolizumab
- Where
- 13 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- Turnstone Biologics, Corp.
Head and Neck Cancer, Cancer of the Head and Neck
Fluorescence Imaging in Head and Neck Cancer
Fluorescent technology continues to advance in the detection of sentinel lymph nodes (SLNs). Currently, this requires switching from near-infrared light to white light to be able to identify the fluorescent tissue contrasting…
- Trial name
- NCT03297957
- Testing
- Hands-free goggle system
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Washington University School of Medicine
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck
This phase I trial studies the side effects and best dose of TLR8 Agonist VTX-2337 when given together with cetuximab in treating patients with locally advanced, recurrent, or metastatic squamous cell cancer of the head and neck…
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01334177
- Testing
- TLR8 agonist VTX-2337, cetuximab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Washington
Low Risk, Papillary Thyroid Cancer
Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers
To track the outcomes of patients who have been treated with RFA and its long-term effectiveness, and to learn more about the quality of life of patients who have received RFA in this study.
- Conditions
- Low Risk, Papillary Thyroid Cancer, Radiofrequency Ablation
- Trial name
- NCT07140757
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Colon Cancer, Esophageal Carcinoma
A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
The purpose of this study is to evaluate the safety and efficacy of EpCAM-specific CAR T Cells infusion for EpCAM positive Cancer.
- Conditions
- Colon Cancer, Esophageal Carcinoma, Pancreatic Cancer, Prostate Cancer
- Trial name
- CARTEPC (NCT03013712)
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Chengdu Medical College
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.